Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elosulfase alfa (Vimizim) real-world study in MPS IVA in China
CTR20201095Phase 4Terminated
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Jun 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of elosulfase alfa in Mucopolysaccharidosis type IV A, sponsored by BioMarin Pharmaceutical Inc.. Started Jun 2020; status: terminated.
02
Drugs
elosulfase alfa
03
Conditions
Mucopolysaccharidosis type IV A
Beyond the preview
Go deeper on CTR20201095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201095.